1. Home
  2. ZYME

as 10-07-2025 3:29pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Founded: 2003 Country:
United States
United States
Employees: N/A City: MIDDLETOWN
Market Cap: 1.2B IPO Year: 2017
Target Price: $20.00 AVG Volume (30 days): 648.0K
Analyst Decision: Buy Number of Analysts: 7
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.98 EPS Growth: N/A
52 Week Low/High: $9.03 - $17.70 Next Earning Date: 10-30-2025
Revenue: $122,867,000 Revenue Growth: 95.94%
Revenue Growth (this year): 107.76% Revenue Growth (next year): 2.35%

Share on Social Networks: